Levormeloxifene

Levormeloxifene
Clinical data
Other names	Levomeloxifene; 6720-CDRI; NNC-460020
Identifiers
	IUPAC name 1-(2-[4-[(3R,4R)-7-Methoxy-2,2-dimethyl-3-phenyl-3,4-dihydro-2H-chromen-4-yl]phenoxy]ethyl)pyrrolidine;
CAS Number	78994-23-7 ;
PubChem CID	35805;
ChemSpider	32935 ;
UNII	9512UKZ352;
ChEMBL	ChEMBL301327 ;
CompTox Dashboard (EPA)	DTXSID301317017 DTXSID6046844, DTXSID301317017 ;
Chemical and physical data
Formula	C30H35NO3
Molar mass	457.614 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O(c1ccc(cc1)[C@@H]3c4c(OC([C@H]3c2ccccc2)(C)C)cc(OC)cc4)CCN5CCCC5;
	InChI InChI=1S/C30H35NO3/c1-30(2)29(23-9-5-4-6-10-23)28(26-16-15-25(32-3)21-27(26)34-30)22-11-13-24(14-12-22)33-20-19-31-17-7-8-18-31/h4-6,9-16,21,28-29H,7-8,17-20H2,1-3H3/t28-,29+/m1/s1 ; Key:XZEUAXYWNKYKPL-WDYNHAJCSA-N ;
	(what is this?) (verify)

Levormeloxifene (INNTooltip International Nonproprietary Name; developmental code names 6720-CDRI, NNC-460020) is a selective estrogen receptor modulator (SERM) which was being developed as an alternative to estrogen replacement therapy for the treatment and prevention of postmenopausal bone loss but did not complete development and hence was never marketed.^[1] The development was stopped because of a high incidence of gynecological side effects during clinical trials.^[2] Levormeloxifene is the levorotatory enantiomer of ormeloxifene, which, in contrast, has been marketed, though rather as a hormonal contraceptive.